<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35416407</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-7843</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>130</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
          <ISOAbbreviation>Basic Clin Pharmacol Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model.</ArticleTitle>
        <Pagination>
          <StartPage>623</StartPage>
          <EndPage>631</EndPage>
          <MedlinePgn>623-631</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcpt.13731</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There is increasing scientific evidence to substantiate using low-dose glucagon as a supplement to insulin therapy in artificial pancreata for diabetes mellitus type 1. The delivery of both these hormones intraperitoneally would mimic normal physiology. However, our knowledge of the pharmacological properties of glucagon after intraperitoneal administration is limited. This study compared the pharmacokinetics of glucagon after intraperitoneal, subcutaneous and intravenous administration and the pharmacodynamic effects of glucagon on glucose metabolism after intraperitoneal and subcutaneous administration in a pig model.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Twelve pigs were included. Glucagon was administered intraperitoneally, subcutaneously and intravenously in a randomised order. Arterial samples were collected every 2-10 min for 150 min to determine plasma glucagon and blood glucose concentrations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The bioavailability of glucagon was significantly lower after intraperitoneal compared with subcutaneous administration with a median difference (95% confidence interval) of 13% (4-22). The effect of glucagon on glucose metabolism was equal after intraperitoneal and subcutaneous administration.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intraperitoneal glucagon administration resulted in lower systemic glucagon exposure than subcutaneous administration without loss of efficiency. We interpret this as evidence of a major first-pass metabolism of glucagon in the liver.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Basic &amp; Clinical Pharmacology &amp; Toxicology published by John Wiley &amp; Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Teigen</LastName>
            <ForeName>Ingrid Anna</ForeName>
            <Initials>IA</Initials>
            <Identifier Source="ORCID">0000-0002-2389-4444</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Åm</LastName>
            <ForeName>Marte Kierulf</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carlsen</LastName>
            <ForeName>Sven Magnus</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christiansen</LastName>
            <ForeName>Sverre Christian</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
        <NlmUniqueID>101208422</NlmUniqueID>
        <ISSNLinking>1742-7835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-92-5</RegistryNumber>
          <NameOfSubstance UI="D005934">Glucagon</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005934" MajorTopicYN="Y">Glucagon</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007332" MajorTopicYN="N">Insulin Infusion Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">artificial pancreas</Keyword>
        <Keyword MajorTopicYN="N">diabetes mellitus type 1</Keyword>
        <Keyword MajorTopicYN="N">glucagon</Keyword>
        <Keyword MajorTopicYN="N">intraperitoneal infusion</Keyword>
        <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>8</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35416407</ArticleId>
        <ArticleId IdType="doi">10.1111/bcpt.13731</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Downes MA. Glucagon. Review. Emerg Med. 2003;15(5-6):480-485. doi:10.1046/j.1442-2026.2003.00506.x</Citation>
        </Reference>
        <Reference>
          <Citation>Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973;182(4108):171-173. doi:10.1126/science.182.4108.171</Citation>
        </Reference>
        <Reference>
          <Citation>Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health. 2006;42(3):108-111. doi:10.1111/j.1440-1754.2006.00807.x</Citation>
        </Reference>
        <Reference>
          <Citation>Haymond MW, DuBose SN, Rickels MR, et al. Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes. J Clin Endocrinol Metab. 2017;102(8):2994-3001. doi:10.1210/jc.2017-00591</Citation>
        </Reference>
        <Reference>
          <Citation>Taleb N, Haidar A, Messier V, Gingras V, Legault L, Rabasa-Lhoret R. Glucagon in artificial pancreas systems: potential benefits and safety profile of future chronic use. Diabetes Obes Metab. 2017;19(1):13-23. doi:10.1111/dom.12789</Citation>
        </Reference>
        <Reference>
          <Citation>Wilson LM, Jacobs PG, Ramsey KL, et al. Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial. Diabetes Care. 2020;43(11):2721-2729. doi:10.2337/dc19-2267</Citation>
        </Reference>
        <Reference>
          <Citation>Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther. 1971;178(3):562-564.</Citation>
        </Reference>
        <Reference>
          <Citation>Dirnena-Fusini I, Åm MK, Carlsen SM, Fougner AL, Christiansen SC. The metabolic effects of continous intra-peritoneal insulin infusion, a systematic review. Presented at: Advanced Technologies &amp; Treatments for Diabetes; 2020; Madrid.</Citation>
        </Reference>
        <Reference>
          <Citation>Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Intraperitoneal, subcutaneous and intravenous glucagon delivery and subsequent glucose response in rats: a randomized controlled crossover trial. BMJ Open Diabetes Res Care. 2018;6(1):e000560. doi:10.1136/bmjdrc-2018-000560</Citation>
        </Reference>
        <Reference>
          <Citation>Loxham SJ, Teague J, Poucher SM, de Schoolmeester J, Turnbull AV, Carey F. Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy. J Pharmacol Toxicol Methods. 2007;55(1):71-77. doi:10.1016/j.vascn.2006.03.005</Citation>
        </Reference>
        <Reference>
          <Citation>Zlotnik A, Gruenbaum BF, Klin Y, et al. The effects of insulin, glucagon, glutamate, and glucose infusion on blood glutamate and plasma glucose levels in naive rats. J Neurosurg Anesthesiol. 2011;23(4):323-328. doi:10.1097/ANA.0b013e3182299b15</Citation>
        </Reference>
        <Reference>
          <Citation>Teigen IA, Åm MK, Carlsen SM, Christiansen SC. Pharmacokinetics of intraperitoneally delivered glucagon in pigs: a hypothesis of first pass metabolism. Eur J Drug Metab Pharmacokinet. 2021;46(4):505-511. doi:10.1007/s13318-021-00692-2</Citation>
        </Reference>
        <Reference>
          <Citation>Åm MK, Dirnena-Fusini I, Fougner AL, Carlsen SM, Christiansen SC. Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels. Sci Rep. 2020;10(1):13735. doi:10.1038/s41598-020-70813-5</Citation>
        </Reference>
        <Reference>
          <Citation>Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8. doi:10.1111/bcpt.13492</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical Pharmacology 2020 database. Glucagon. Elsevier Inc Accessed May 20, 2020. https://www.clinicalkey.com/pharmacology/login</Citation>
        </Reference>
        <Reference>
          <Citation>MATLAB version R2020b (9.9.0.1467703). MathWorks, Inc. Accessed June 10, 2021. www.mathworks.com</Citation>
        </Reference>
        <Reference>
          <Citation>GraphPad Software LLC. GraphPad Prism version 9.1.2 (225) for macOS. Accessed June 14, 2021. www.graphpad.com</Citation>
        </Reference>
        <Reference>
          <Citation>Morris C, Baker J. Glucagon. StatPearls Publishing 2021. Updated June 14, 2021. Accessed July 2, 2021, https://www.ncbi.nlm.nih.gov/books/NBK559195/</Citation>
        </Reference>
        <Reference>
          <Citation>Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: a systematic review and meta-analysis. PLoS One. 2021;16(4):e0249611. doi:10.1371/journal.pone.0249611</Citation>
        </Reference>
        <Reference>
          <Citation>Schnoor J, Schreck R, Baumert JH, Grosse-Siestrup C, Rossaint R, Unger JK. Influence of differences in body weight and volume management on experimental results in porcine models. Int J Artif Organs. 2004;27(11):924-934. doi:10.1177/039139880402701104</Citation>
        </Reference>
        <Reference>
          <Citation>Lockton JA, Poucher SM. Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge. J Pharmacol Toxicol Methods. 2007;55(1):86-90. doi:10.1016/j.vascn.2006.03.009</Citation>
        </Reference>
        <Reference>
          <Citation>Blauw H, Wendl I, DeVries JH, Heise T, Jax T. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't. Diabetes Obes Metab. 2016;18(1):34-39. doi:10.1111/dom.12571</Citation>
        </Reference>
        <Reference>
          <Citation>Castle JR, Bakhtiani PA, Cai Y, et al. Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system. Diabetes Care. 2015;38(11):2115-2119. doi:10.2337/dc15-0754</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
